Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$31.20
-3.3%
$30.14
$23.23
$42.29
$1.00B0.64397,390 shs219,382 shs
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$4.28
-3.8%
$3.47
$2.01
$5.64
$284.73M1.521.23 million shs1.59 million shs
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
$53.85
-2.0%
$43.38
$26.70
$91.83
$1.10B2.6370,355 shs394,544 shs
ProKidney Corp. stock logo
PROK
ProKidney
$3.15
-10.5%
$1.33
$0.46
$7.13
$922M1.263.62 million shs6.55 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
-3.29%-4.06%+5.41%+15.51%-2.32%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-3.82%+5.16%+41.72%+50.18%+68.50%
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
-1.98%+6.55%+25.32%+59.37%-2.29%
ProKidney Corp. stock logo
PROK
ProKidney
-10.51%-30.62%+352.39%+298.28%+36.96%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
4.4013 of 5 stars
3.42.00.03.03.40.82.5
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
0.8832 of 5 stars
3.40.00.00.00.00.00.6
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
2.4927 of 5 stars
4.41.00.00.02.01.70.0
ProKidney Corp. stock logo
PROK
ProKidney
3.5388 of 5 stars
3.24.00.00.03.83.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2.75
Moderate Buy$43.7540.22% Upside
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2.83
Moderate Buy$11.70173.36% Upside
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
2.78
Moderate Buy$94.1174.77% Upside
ProKidney Corp. stock logo
PROK
ProKidney
2.40
Hold$6.2598.41% Upside

Current Analyst Ratings Breakdown

Latest CRDF, PRAX, PROK, and COLL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/18/2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$105.00
7/15/2025
ProKidney Corp. stock logo
PROK
ProKidney
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $8.00
7/14/2025
ProKidney Corp. stock logo
PROK
ProKidney
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $7.00
7/9/2025
ProKidney Corp. stock logo
PROK
ProKidney
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $9.00
7/8/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$19.00
7/8/2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$97.00 ➝ $115.00
6/30/2025
ProKidney Corp. stock logo
PROK
ProKidney
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Underperform$3.00 ➝ $1.00
6/24/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$3.50
6/18/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
6/12/2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00
6/2/2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform$97.00
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$631.45M1.59$12.33 per share2.53$7.10 per share4.39
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$587K485.06N/AN/A$1.86 per share2.30
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
$8.12M135.05N/AN/A$23.90 per share2.25
ProKidney Corp. stock logo
PROK
ProKidney
$80K11,525.06N/AN/A($3.41) per share-0.92
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$69.19M$1.2225.575.18N/A6.61%99.08%15.14%8/6/2025 (Estimated)
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$45.43M-$0.92N/AN/AN/A-8,308.50%-76.45%-62.85%8/14/2025 (Estimated)
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
-$182.82M-$10.72N/AN/AN/A-2,137.48%-50.42%-46.74%8/12/2025 (Estimated)
ProKidney Corp. stock logo
PROK
ProKidney
-$61.19M-$0.60N/AN/AN/AN/AN/A-15.03%8/8/2025 (Estimated)

Latest CRDF, PRAX, PROK, and COLL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.88N/AN/AN/A$182.26 millionN/A
8/14/2025Q2 2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.19N/AN/AN/A$0.10 millionN/A
8/12/2025Q2 2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
-$3.40N/AN/AN/A$0.16 millionN/A
8/8/2025Q2 2025
ProKidney Corp. stock logo
PROK
ProKidney
-$0.14N/AN/AN/AN/AN/A
5/12/2025Q1 2025
ProKidney Corp. stock logo
PROK
ProKidney
-$0.16-$0.13+$0.03-$0.13N/A$0.23 million
5/8/2025Q1 2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.50$1.49-$0.01$0.07$174.96 million$177.76 million
5/8/2025Q1 2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.19-$0.20-$0.01-$0.20$0.09 million$0.11 million
5/2/2025Q1 2025
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
-$3.20-$3.29-$0.09-$3.29$0.20 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/AN/AN/AN/AN/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/AN/AN/AN/AN/A
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
N/AN/AN/AN/AN/A
ProKidney Corp. stock logo
PROK
ProKidney
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
3.30
1.08
1.01
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/A
6.22
6.22
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
N/A
8.44
8.44
ProKidney Corp. stock logo
PROK
ProKidney
N/A
10.96
10.96

Institutional Ownership

CompanyInstitutional Ownership
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
16.29%
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
67.84%
ProKidney Corp. stock logo
PROK
ProKidney
51.59%

Insider Ownership

CompanyInsider Ownership
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2.51%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
7.70%
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
2.70%
ProKidney Corp. stock logo
PROK
ProKidney
41.49%
CompanyEmployeesShares OutstandingFree FloatOptionable
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
21032.13 million31.33 millionOptionable
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2066.53 million61.40 millionOptionable
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
11020.37 million19.82 millionOptionable
ProKidney Corp. stock logo
PROK
ProKidney
3292.70 million171.26 millionOptionable

Recent News About These Companies

ProKidney (NASDAQ:PROK) Shares Down 4.1% - Time to Sell?
Best Momentum Stocks to Buy for July 17th
New Strong Buy Stocks for July 17th
ProKidney gains pivotal therapy advancement step with FDA
ProKidney (NASDAQ:PROK) Trading Up 7.5% Following Analyst Upgrade
ProKidney (NASDAQ:PROK) Shares Gap Up on Analyst Upgrade

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Collegium Pharmaceutical stock logo

Collegium Pharmaceutical NASDAQ:COLL

$31.20 -1.06 (-3.29%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$31.20 0.00 (-0.02%)
As of 07/18/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Cardiff Oncology stock logo

Cardiff Oncology NASDAQ:CRDF

$4.28 -0.17 (-3.82%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$4.36 +0.09 (+1.99%)
As of 07/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Praxis Precision Medicines stock logo

Praxis Precision Medicines NASDAQ:PRAX

$53.85 -1.09 (-1.98%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$53.86 +0.00 (+0.01%)
As of 07/18/2025 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

ProKidney stock logo

ProKidney NASDAQ:PROK

$3.15 -0.37 (-10.51%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$3.20 +0.04 (+1.43%)
As of 07/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.